Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial

News | 12. 08. 2023

Aura Biosciences

BOSTON--Dec. 7, 2023-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the first patient has been dosed in the global Phase 3 CoMpass trial evaluating the safety and efficacy of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma.